• Inclusion criterion 11 was updated to make clear that the intention was that antihypertensive subjects would be on a stable antihypertensive regimen during the study. • The following exclusion criteria were revised to the text as given in the CSR to capture the target subject population: exclusion criteria 5, 9, 12, 13, 14, 17, 19, 20, 25, 26. Text in other parts of the CSP were updated as appropriate to reflect changes in the exclusion criteria. • Additional information on concomitant medications was added as follows:  Generic substitutions of all stable medications for underlying diseases were allowed during the study. Changing a medication within the same therapeutic class was also permitted during the study.  Any subject who initiated a high dose or increased to a higher dose of Vitamin E (≥800 IU/day) during the course of the study had to undergo ET procedures (including liver biopsy and imaging if beyond Week 36). • Changes were made to update the NCI CTCAE version and provide clarification around documenting and reporting of AEs. • At home pregnancy tests were added at Weeks 52, 60, and 68 for females of childbearing potential. Due to the 8-week timeframe between clinic visits at Weeks 48, 56, and 72, these at home pregnancy tests were added to confirm subjects did not become pregnant during the extended time between visits. To determine the results of the pregnancy tests, additional phone contacts were added • The number of laboratory tests conducted to assess lipids and cardiovascular risk were reduced. These were no longer deemed necessary based on data readouts from previous studies.

The screening time was extended from 8 to 10 weeks because additional time was needed to allow more flexibility for completion of all screening procedures in a sequential manner • The inclusion criteria for MRI-PDFF ≥8% and AST >30 IU/L were added to further refine the subject population eligible for study entry and thus increase the probability of resulting in eligible liver biopsy criteria • To avoid unnecessary burden on potential subjects, the inclusion criteria were modified to specify that screening assessments should be performed in a sequential manner and the liver biopsy should only be performed once the subject satisfied all other eligibility criteria • To avoid confusion noted by the sites with regard to the duration of a month (i.e., 28, 30, or 31 days), durations were changed from months to corresponding weeks throughout the CSP • Wording on Screening and use of concomitant medications was clarified with regard to rescreening options for subjects who required a medically necessary dose modification with an existing medication • The schedule of assessments was modified so that for subjects who discontinued between Weeks 10 and 12, the MRI/MRE that would have been conducted at Week 12 was to be conducted at the EOT visit • The wording of ECG requirements was revised to clarify ECG repeat requirements because the original language was proving to be confusing to sites. Normal ranges for ECG assessments were provided. • Due to the COVID 19 pandemic, provisions were added to clarify options for rescreening subjects who were affected by COVID 19 • Wording regarding the reporting of AEs was revised to simplify the recording requirements for AEs and all AEs collected would be entered into the eCRF • Clarified that DLQI was only to be completed at each in-clinic visit as opposed to all visits • The wording was revised to emphasize the need for reviewing eligibility criteria and detailing the definition of women childbearing potential.